Clinical Trial Update: Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency [Phase 2]

View source ↗

Summary

Phase 2 trial of Alvelestat (MPH966) for Alpha-1 antitrypsin deficiency has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Alvelestat (alvelestat)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations | Phase 2 | Status: COMPLETED | Results posted: 2024-07-09